| Income Statement | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 |
|---|---|---|---|---|
| Total revenue-Rental Third Party | NaN | NaN | NaN | 50* |
| Total revenue-Rental Related Party | NaN | NaN | NaN | 28* |
| Total revenue-Product Revenue | NaN | NaN | NaN | -214* |
| Total revenue-Infusion Technology | NaN | NaN | NaN | -33* |
| Cost of product revenue-Infusion Technology Revenue | NaN | NaN | NaN | 13* |
| Total revenue | 179 | 211 | 240 | 182* |
| Cost of revenue | 8 | 12 | 9 | 1* |
| General and administrative | 2,140 | 2,270 | 2,838 | 5,242* |
| Research and development | 4,853 | 4,529 | 7,484 | 8,148* |
| Depreciation and amortization | 48 | 55 | 50 | 66* |
| In-process research and development expense | NaN | NaN | NaN | 0* |
| Loss on impairment of goodwill | 0 | 0 | NaN | 775* |
| Loss from operations | -6,870 | -6,655 | -10,141 | -14,231* |
| Unrealized (gain) loss on investment - cyclo | NaN | NaN | NaN | 3,493* |
| Interest income | 286 | 337 | 399 | 436* |
| Unrealized (gain) loss on convertible notes receivable, due from cyclo | NaN | NaN | NaN | 1,089* |
| Interest expense | 6 | 161 | 160 | 168* |
| Gain on settlement of accounts payable and convertible notes payable | 3,723 | 201 | NaN | NaN |
| Other income (loss), net | -25 | -1 | 115 | 82* |
| Loss on initial investment in day three upon acquisition | NaN | NaN | NaN | 0* |
| Realized loss on investment in equity securities | NaN | NaN | NaN | 0* |
| Realized gain on investment - cyclo | NaN | NaN | NaN | 0* |
| Realized loss on available-for-sale securities | 0 | 0 | 0 | -404* |
| Unrealized gain on investment - hedge funds | NaN | NaN | NaN | 0* |
| Unrealized loss on investment - cyclo | 0 | 0 | 0 | NaN |
| Recovery of receivables from cornerstone | NaN | NaN | NaN | 0* |
| Unrealized (gain) loss on convertible notes receivable, due from cyclo | 0 | 0 | 0 | NaN |
| Loss before income taxes | -2,892 | -6,279 | -9,787 | -9,703* |
| Equity in loss of day three | NaN | NaN | NaN | 0* |
| (provision for) benefit from income taxes | 6 | 48 | 10 | 1,046* |
| Consolidated net loss | -2,898 | -6,327 | -9,797 | -10,749* |
| Net income (loss) attributable to noncontrolling interests | 1,328 | 90 | 19 | -907* |
| Net loss attributable to rafael holdings, inc | -4,226 | -6,417 | -9,816 | -9,842 |
| Basic EPS | -0.08 | -0.13 | -0.19 | -0.253 |
| Diluted EPS | -0.08 | -0.13 | -0.19 | -0.253 |
| Basic Average Shares | 51,229,576 | 51,226,095 | 51,184,407 | 38,965,308 |
| Diluted Average Shares | 51,229,576 | 51,226,095 | 51,184,407 | 38,965,308 |
Rafael Holdings, Inc. (RFL)
Rafael Holdings, Inc. (RFL)